Vitrolife group at ASRM 2024

19-23 october 2024, Denver, Colorado

Presentations from ASRM 2024

If you missed any of our presentations from our Academy Studio, we have collected them below.

Webinar: 'Embryo Quality Control with PGT-A Plus'

Renowned genetic counselors Lauri Black and Alyssa Snider discuss how the clinical application of PGT-A can be improved by combining NGS and SNP technologies. Beyond ploidy analysis, they emphasize the importance of quality control in detecting DNA contamination and other potential sources of test discrepancies.

This presentation was part of Vitrolife Group live Academy Studios from ASRM 2024.

Webinar: 'Advancing Carrier Screening: clinical implications, customized panels, and the need for consistency in gamete donation'

Julio Martin, Product Director for Monogenic Tests, explains the universal approach to expanded carrier screening through whole exome sequencing and its associated clinical benefits. His presentation highlights matching reports as a key strategy in a successful gamete donation program.

This presentation was part of Vitrolife Group live Academy Studios from ASRM 2024.

Webinar: 'Unveiling the Impact of the Endometrial Microbiome: why testing the reproductive tract microbiota is crucial in infertility treatment'

Pathogenic bacteria are present in the endometrium of 30% of infertile women. By testing the endometrial microbiome, these bacteria can be identified and effectively treated. Research by Prof. Carlos Simón’s team has demonstrated that restoring a healthy microbiome is crucial for the success of fertility treatments.

This presentation was part of Vitrolife Group live Academy Studios from ASRM 2024.

Webinar: 'EMBRACE: what to expect from embryo viability and clinical outcomes in a niPGT-A program'

Dr. Sakkas explains that as the blastocyst develops, it actively releases DNA into the culture media, with both the quantity and quality of the DNA likely increasing between days 5 and 6. His most recent publication demonstrates that extending embryo culture to day 6 for niPGT-A screening does not compromise embryo viability or affect pregnancy outcomes, making it a safe alternative for patients who wish to avoid embryo biopsy while still pursuing chromosomal testing.

This presentation was part of Vitrolife Group live Academy Studios from ASRM 2024.

For decades of innovation, we have made a difference

Our passion and commitment to making a difference in reproductive health has never been stronger.

The Vitrolife Group has a vision with a purpose: to enable people to fulfill the dream of having a healthy baby. Together, we combine high-quality medical devices with pioneering genetic testing solutions, covering the entire reproductive-health journey. Grounded in science, our innovations provide consistent performance, workflow efficiency, and guaranteed quality. Together, we create excellence in reproductive health!

Discover our values through the voices of Vitrolife Group employees

Highlights at ASRM 2024

 

Do you want more information about our products?

Download brochures

Igenomix's highlights at ASRM 2024

 

Get in touch

Don't hesitate to contact us if you have any questions or want more information about our new products.
Fill out the form below and we'll get back to you as soon as we can.

 













We kindly ask that you do not send us any health data or any other sensitive personal data here. Please read more in the Vitrolife Group’s Privacy notice for website visitors: Privacy policy | Vitrolife Group about how we process your personal data to communicate with you about inquiries or comments made by you.

Hidden Section (Automatic)




Hidden Section